Sign in to view content

Safety and Efficacy of Brepocitinib, a TYK2/JAK1 Inhibitor, in Active Non-Infectious Uveitis: 24-Week Results from a 52-Week Phase 2 Study (NEPTUNE)

Robert C. Wang, MD, FASRS

Video
Published 2024

Related

Prospective Use of Imaging Quantification of Inflammation: Determining Uveitis Activity and Correlating to Visual Acuity
Jordan D Deaner, MD
Annual Meeting Talks
2021
Multifocal Choroiditis and Panuveitis- Schlaegel lines
Manuel Ángel Alcántara Delgado, MD
Retina Image Bank: Images of the Week
2022
What Now? Diagnostic Challenges in Retina
Basil K Williams, MD
Akbar Shakoor, MD
Webinars and Journal Clubs
2023

Category: Inflammatory and Infectious Diseases

See more